Fact sheet: OMW AXA Framlington Biotech

Fund information
Fund name
OMW AXA Framlington Biotech Pn
Fund manager company
Old Mutual Wlth Life As Co Ltd
Fund type
Pension Fund
Fund managers
  • Linden Thomsonsince 04/07/2012
Underlying fund
AXA Framlington Biotech
Fund objective
The OMW AXA Framlington Biotech fund invests solely in the AXA Framlington Biotech fund, a UK authorised Unit Trust managed by AXA Investment Managers UK Limited. The underlying fund seeks to provide long-term capital appreciation by investing principally in equity securities of companies in the biotechnology, genomic and medical research industries worldwide.Investments in the underlying fund tend to be volatile and investors should expect an above average price increase or decrease.Investments in emerging markets tend to be volatile and are usually considered to carry a greater degree of risk than investments in established markets. This relates to dealing, settlement and custody practices, the possibility of political or economic instability, and developing legal, fiscal and regulatory structures.The underlying fund invests into a relatively small number of assets, or into individual countries or a specific market sector. Such concentrated portfolios give rise to more risk than where investments are spread across a larger number of assets, countries or market sectors.The underlying fund may be denominated in or hold assets in a currency other than Sterling. The performance of the fund may therefore rise and fall as a result of exchange rate fluctuations.Some of the investments in the underlying fund can be difficult to sell at times, which could affect the price of units.It should be noted that the performance of the OMW fund will not match that of the underlying investment due to OMW fund charges, appropriate taxation adjustment and the OMW investment process.
Benchmark
  • No Specified Index
Investment style
Growth
Investment method
Shares
Quick stats
1 Year return
-6.4%
1 Year rank in sector
496/510
Sector
PN Specialist
Yield
-
Fund size
£12m (£19m last year)
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
214
Bid price
292.1
Offer price
307.4
Top in this sector
Fund name1 Year
OMW Neptune Rus + Grtr Rus40.3%
ReAssure AL NptRu&GtrRus Pn40%
L&G Nep Russia&Gtr Russia Pn39.8%
OMW InvescoPerpetualEmgEurpn34.7%
SIP Sanlam Gbl Fin Pn34.5%
...more in PN Specialist

Performance snapshot

Holdings snapshot

  • USA84.2%
    UK3.1%
    Switzerland3.1%
    France2.4%
    Belgium2.4%
  • Biotechnology/Medical79.1%
    Pharmaceuticals13.5%
    Technology3.6%
    Money Market1.8%
    Electronic & Electrical Equipment1.2%
  • US Equities84.2%
    UK Equities3.1%
    Swiss Equities3.1%
    French Equities2.4%
    Belgian Equities2.4%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund3%1.4%9.2%-6.4%49.3%211.1%
Sector-2%-0.6%6.3%7.4%19.4%41.4%
Rank within sector4 / 546100 / 544162 / 531496 / 51029 / 3864 / 314
Quartile1st1st2nd4th1st1st
Calendar performance
 YTD - 20162015201420132012
Fund-7.9%9.9%47.4%60.7%25.3%
Sector8.3%2%7.2%11%7.7%
Rank within sector512 / 51429 / 4504 / 3884 / 3574 / 318
Quartile4th1st1st1st1st
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
0.78
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
2.69
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
0.47
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
25.57
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
22.32
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
0.39
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.39
Price movement
52 week high318
52 week low229.6
Current bid price292.1
Current offer price307.4
Current mid price-
Region
1USA84.18%
2UK3.11%
3Switzerland3.08%
4France2.41%
5Belgium2.35%
6Sweden2.17%
7Money Market1.82%
8Germany0.49%
9Canada0.39%
Industry sector
1Biotechnology/Medical79.07%
2Pharmaceuticals13.5%
3Technology3.62%
4Money Market1.82%
5Electronic & Electrical Equipment1.22%
6Health Care0.77%
Asset type
1US Equities84.18%
2UK Equities3.11%
3Swiss Equities3.08%
4French Equities2.41%
5Belgian Equities2.35%
6Swedish Equities2.17%
7Money Market1.82%
8German Equities0.49%
9Canadian Equities0.39%
Individual holdings
1GILEAD SCIENCES INC9.8%
2BIOGEN INC9%
3CELGENE CORP8.6%
4ALEXION PHARMACEUTICALS INC7.7%
5VERTEX PHARMACEUTICAL5.3%
6REGENERON PHARMACEUTICALS INC4.8%
7INCYTE CORP4.6%
8AMGEN INC4.5%
9BIOMARIN PHARMACEUTICAL3.6%
Management
Fund manager group
Skandia
Fund manager company
Old Mutual Wlth Life As Co Ltd
Fund type
Pension Fund
Fund objective
The OMW AXA Framlington Biotech fund invests solely in the AXA Framlington Biotech fund, a UK authorised Unit Trust managed by AXA Investment Managers UK Limited. The underlying fund seeks to provide long-term capital appreciation by investing principally in equity securities of companies in the biotechnology, genomic and medical research industries worldwide.Investments in the underlying fund tend to be volatile and investors should expect an above average price increase or decrease.Investments in emerging markets tend to be volatile and are usually considered to carry a greater degree of risk than investments in established markets. This relates to dealing, settlement and custody practices, the possibility of political or economic instability, and developing legal, fiscal and regulatory structures.The underlying fund invests into a relatively small number of assets, or into individual countries or a specific market sector. Such concentrated portfolios give rise to more risk than where investments are spread across a larger number of assets, countries or market sectors.The underlying fund may be denominated in or hold assets in a currency other than Sterling. The performance of the fund may therefore rise and fall as a result of exchange rate fluctuations.Some of the investments in the underlying fund can be difficult to sell at times, which could affect the price of units.It should be noted that the performance of the OMW fund will not match that of the underlying investment due to OMW fund charges, appropriate taxation adjustment and the OMW investment process.
Benchmark
  • No Specified Index
Investment style
Growth
Investment method
Shares
Fund managers
NameSinceBiography
Linden Thomson04/07/2012Linden Thomson joined AXA IM in June 2011 as sector specialist on the Healthcare equity desk. Linden joined AXA IM from Hedge Fund Clear River Capital where she was responsible for fundamental stock research across the global pharmaceutical and biotechnology sectors. Prior to that she worked for Goldman Sachs on the sell side where she was based in the healthcare research team with specific focus on the biotechnology sector. She graduated from Edinburgh University with a BSc in Medical Microbiology and is a CFA Charterholder.
Compliance
No data available.
Domicile
No data available.
Fund for sale in
United Kingdom
OMW AXA Framlington Biotech Pn
Initial charge-
Annual charge-
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)1.33%
Bid price292.1
Offer price307.4
Mid price-
CurrencyGBX
Price updated02/12/2016
Type-
Institutional or retail classRetail
Domicile-
Citi codeXK01
OMW AXA Framlington Biotech SP
Initial charge-
Annual charge-
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)1.33%
Bid price-
Offer price-
Mid price345.5
CurrencyGBX
Price updated02/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeZX42
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.